

PATENT Customer No. 22,852 Attorney Docket No. 9914.0004-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
Mary Jane Cardosa et al.) Group Art Unit: 1648
Application No.: 10/786,380	Examiner: STACY BROWN CHEN
Filed: February 24, 2004	Confirmation No.: 3579
]

For: RECOMBINANT MVA VIRUS EXPRESSING DENGUE VIRUS

ANTIGENS, AND THE USE THEREOF IN VACCINES

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicant brings to the attention of the Examiner the document on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance and is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

A copy of the listed non-patent literature document is attached.

06/21/2007 MAHMED1 00000012 10786380 01 FC:1806 180.00 OP

Application No.: 10/786,380

Applicant respectfully requests that the Examiner consider the listed documents

and indicate that they were considered by making appropriate notations on the attached

form.

This submission does not represent that a search has been made or that no

better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claims in the application and Applicant determines

that the cited document does not constitute "prior art" under United States law,

Applicant reserves the right to present to the office the relevant facts and law regarding

the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the

patentability of the disclosed invention over the listed documents, should one or more of

the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please

By:

charge the fee to Deposit Account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, L.L.P.

Dated: <u>June 20, 2007</u>

Sálvatore J. Artigo

Reg. No. 46,063

Telephone: 202-408-4160 Facsimile: 202-408-4400

E-mail: arrigos@finnegan.com

IDS Form PTO/SB/08:	Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of

		/00 D = >		
Complete if Known				
Application Number	10/786,380	JUN 2 0 200		
Filing Date	February 24, 2004	10		
First Named Inventor	Mary Jane Cardosa	127		
Art Unit	1648	To rough		
Examiner Name	Stacy Brown Chen	10000		
Attorney Docket Number	09914-0004-00000			

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS						
Examiner		Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
Initials	No.1	Number-Kind Code ² (if known)			Relevant Passages or Relevant Figures Appear	
		US-				
		US-		<u>,</u>		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

	NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶		
		G. ANTOINE, et al., "The Complete Genomic Sequence of the Modified Vaccinia Ankara Strain: Comparison with Other Orthopoxviruses," <i>Virology</i> 244:365-396 (1998)			
		·			

Examiner	Date	
Signature	Considered	